These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35681706)

  • 1. Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.
    Mateu-Albero T; Marcos-Jimenez A; Wissmann S; Loscertales J; Terrón F; Stein JV; Muñoz-Calleja C; Cuesta-Mateos C
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
    Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C
    Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia.
    Rey-Barroso J; Munaretto A; Rouquié N; Mougel A; Chassan M; Gadat S; Dewingle O; Poincloux R; Cadot S; Ysebaert L; Quillet-Mary A; Dupré L
    Haematologica; 2024 Mar; 109(3):809-823. PubMed ID: 37381758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
    Mateu-Albero T; Marcos-Jimenez A; Delgado-Wicke P; Terrón F; Loscertales J; López-Matencio JMS; Muñoz-Calleja C; Cuesta-Mateos C
    Hematol Oncol; 2023 Dec; 41(5):869-876. PubMed ID: 37545392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia.
    Patrussi L; Capitani N; Martini V; Pizzi M; Trimarco V; Frezzato F; Marino F; Semenzato G; Trentin L; Baldari CT
    Cancer Res; 2015 Oct; 75(19):4153-63. PubMed ID: 26282174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
    Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
    J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
    Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
    Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
    Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
    Yin Q; Sivina M; Robins H; Yusko E; Vignali M; O'Brien S; Keating MJ; Ferrajoli A; Estrov Z; Jain N; Wierda WG; Burger JA
    J Immunol; 2017 Feb; 198(4):1740-1747. PubMed ID: 28077600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21.
    Zaaboub R; Vimeux L; Contremoulins V; Cymbalista F; Lévy V; Donnadieu E; Varin-Blank N; Martin A; Dondi E
    Blood Adv; 2022 Aug; 6(16):4691-4704. PubMed ID: 35679464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
    Herman SE; Mustafa RZ; Jones J; Wong DH; Farooqui M; Wiestner A
    Clin Cancer Res; 2015 Oct; 21(20):4642-51. PubMed ID: 26089373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.
    Chavez JC; Sahakian E; Pinilla-Ibarz J
    Core Evid; 2013; 8():37-45. PubMed ID: 23717217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
    Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
    Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.